24Mar 2023
Hydrocortisone in Severe Community-Acquired Pneumonia

Hydrocortisone in Severe Community-Acquired Pneumonia

The study is a phase 3, multicenter, double-blind, randomized, controlled trial that investigates whether the use of hydrocortisone can decrease mortality among patients with severe community-acquired pneumonia. The study found that patients who received hydrocortisone had a lower risk of death by day 28 than those who received placebo. The study also found that hydrocortisone reduced the need for mechanical ventilation and vasopressor therapy. The study concludes that the use of hydrocortisone may be beneficial in treating severe community-acquired pneumonia in ICU patients.

  • #family health

Like

Save

Share